Skip to content

Remifentanil for General Anesthesia in Preeclamptics

Remifentanil for c-Section With General Anesthesia in Severe Preeclamptic Patients

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00567957
Enrollment
50
Registered
2007-12-05
Start date
2008-02-29
Completion date
2009-12-31
Last updated
2007-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Pregnancy-Induced, Pre-Eclampsia, Pregnancy Complications

Keywords

pre-eclampsia, remifentanil, anesthesia, general, analgesics, opioid, anesthetics, intravenous, Cesarean section, newborn, maternal haemodynamic

Brief summary

The purpose of this study is to determine whether remifentanil use in preeclamptic patients may blunt hemodynamic response to intubation during general anesthesia for cesarean section.

Detailed description

General anesthesia for cesarean section involves rapid sequence induction with a muscle relaxant and barbiturate followed by endotracheal intubation. Although the use of opioids may blunt haemodynamic responses to endotracheal intubation, they are avoided in pregnant patients due to possible respiratory depressants effects on neonates.Preeclamptic patients response with exaggerated sympathoadrenal reflex to anesthesia induction and intubation. The resulting hypertension and tachycardia may result in cerebrovascular accident, pulmonary edema, arrhythmias, increased myocardial oxygen consumption and fetal hypoxia by uterine vasoconstriction. Several drugs have been used to blunt the hemodynamic disturbances to intubation, but none of them have been implicated for routine use for general anesthesia in preeclamptic patients. Recently remifentanil has started to be used in general anesthesia of high risk obstetric patients. Remifentanil is a μ-opioid receptor agonist that is metabolized by nonspecific blood and tissue esterase hydrolysis. It has a low distribution volume with a context sensitive half life of 3 minutes. Its elimination half life is 12 minutes even after repeated boli. Previously remifentanil use in pregnant patients with cardiac pathology has been reported with minimal neonatal side effects. A randomized controlled study in normal parturient has shown that remifentanil is transferred through placenta and may cause mild neonatal depression that is easily managed. Umbilical artery and vein remifentanil concentrations has shown that remifentanil is quickly redistributed or metabolized in fetus. Thus, remifentanil may be an appropriate drug for induction and maintenance of general anesthesia in severe preeclamptic patients.

Interventions

DRUGRemifentanil

1 microg/kg iv bolus before induction followed by 0.5 microg/kg/min infusion

DRUGSaline

same volume iv bolus before induction followed by same volume infusion

Sponsors

Istanbul University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Severe preeclamptic parturients with single fetus pregnancy with contraindication to regional anesthesia

Exclusion criteria

* Known allergy to study drugs * Known fetal anomaly and /or gestation week and /or estimated to be nonviable (fetal weight \<400 gr, gestational week\<24 weeks) * Known cardiac disease diagnosed prior to pregnancy * Known drug abuse in the parturient * Multifetal gestation * Anticipated difficult airway management (mask ventilation and/or endotracheal intubation).

Design outcomes

Primary

MeasureTime frame
Blood pressureInduction to post-intubation period

Secondary

MeasureTime frame
Heart rateInduction to delivery
Amount of additional drugs and fluids if requiredInduction to delivery
Evaluation of the newbornWithin 10 min following delivery

Countries

Turkey (Türkiye)

Contacts

Primary ContactTulay Ozkan Seyhan, Associate Prof.
tulay2000@e-kolay.net+90 212 631 87 67
Backup ContactMukadder Orhan Sungur, Staff
mosungur@istanbul.edu.tr+90 212 631 87 67

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026